## Hong Xiao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2587026/publications.pdf

Version: 2024-02-01

477173 759055 1,747 29 12 29 citations h-index g-index papers 29 29 29 1655 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Patient and caregiver socioeconomic burden of first-line systemic therapy for advanced gastroesophageal adenocarcinoma. Future Oncology, 2022, 18, 1199-1210.	1.1	7
2	Racial/Ethnic Differences in Age at Menarche and Lifetime Nonmedical Marijuana Use: Results from the NHANES 2005–2016. Journal of Racial and Ethnic Health Disparities, 2021, 8, 448-453.	1.8	2
3	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, The, 2021, 398, 27-40.	6.3	1,237
4	Examining factors associated with adherence to hormonal therapy in breast cancer patients. Research in Social and Administrative Pharmacy, 2020, 16, 574-582.	1.5	5
5	Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. Drug Safety, 2020, 43, 329-338.	1.4	15
6	Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study. Research in Social and Administrative Pharmacy, 2020, 16, 1095-1099.	1.5	3
7	Impact of hepatitis C virus treatment on the risk of nonâ€hepatic cancers among hepatitis C virusâ€infected patients in the US. Alimentary Pharmacology and Therapeutics, 2020, 52, 1592-1602.	1.9	12
8	Maternal plasma concentrations of perfluoroalkyl and polyfluoroalkyl substances during pregnancy and anogenital distance in male infants. Human Reproduction, 2019, 34, 1356-1368.	0.4	32
9	Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration. Pharmacotherapy, 2019, 39, 1042-1052.	1.2	5
10	Prenatal plasma concentrations of Perfluoroalkyl and polyfluoroalkyl substances and neuropsychological development in children at four years of age. Environmental Health, 2019, 18, 53.	1.7	33
11	A Bayesian spatio-temporal analysis on racial disparities in hypertensive disorders of pregnancy in Florida, 2005–2014. Spatial and Spatio-temporal Epidemiology, 2019, 29, 43-50.	0.9	10
12	Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. Inflammatory Bowel Diseases, 2019, 25, 1417-1427.	0.9	89
13	Comparative effectiveness of radiotherapy for earlyâ€stage hormone receptorâ€positive breast cancer in elderly women using realâ€world data. Cancer Medicine, 2019, 8, 117-127.	1.3	7
14	Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review. PharmacoEconomics - Open, 2018, 2, 359-369.	0.9	6
15	Trends in Readmission Rates, Hospital Charges, and Mortality for Patients With Chronic Obstructive Pulmonary Disease (COPD) in Florida From 2009 to 2014. Clinical Therapeutics, 2018, 40, 613-626.e1.	1.1	15
16	Patient and hospital characteristics predictive of inferior vena cava filter usage in venous thromboembolism patients. Medicine (United States), 2018, 97, e0149.	0.4	2
17	Hospitalization metrics associated with hospital-level variation in inferior vena cava filter utilization for patients with venous thromboembolism in the United States: Implications for quality of care. Vascular Medicine, 2018, 23, 365-371.	0.8	2
18	Identification of potential diagnostic biomarkers of cerebral infarction using gas chromatography-mass spectrometry and chemometrics. RSC Advances, 2018, 8, 22866-22875.	1.7	3

#	Article	IF	CITATIONS
19	Identification of potential diagnostic biomarkers of acute pancreatitis by serum metabolomic profiles. Pancreatology, 2017, 17, 543-549.	0.5	25
20	Biological evaluation of phytoconstituents from <i>Polygonum hydropiper</i> . Natural Product Research, 2017, 31, 2053-2057.	1.0	27
21	Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Current Medical Research and Opinion, 2017, 33, 391-400.	0.9	8
22	Geographical Factors Associated with Health Disparities in Prostate Cancer. Cancer Control, 2016, 23, 401-408.	0.7	17
23	Impact of age, race and socio-economic status on temporal trends in late-stage prostate cancer diagnosis in Florida. Spatial Statistics, 2015, 14, 321-337.	0.9	12
24	Geographically-weighted regression analysis of percentage ofÂlate-stage prostate cancer diagnosis in Florida. Applied Geography, 2015, 62, 191-200.	1.7	26
25	A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Research and Treatment, 2015, 151, 27-40.	1.1	110
26	Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation. Pharmaceutical Medicine, 2015, 29, 247-253.	1.0	1
27	Factors Associated with Time-to-Treatment of Prostate Cancer in Florida. Journal of Health Care for the Poor and Underserved, 2013, 24, 132-146.	0.4	7
28	Construction of a comorbidity index for prostate cancer patients linking state cancer registry with inpatient and outpatient data. Journal of Registry Management, 2013, 40, 159-64.	0.1	5
29	Geographical, temporal and racial disparities in late-stage prostate cancer incidence across Florida: A multiscale joinpoint regression analysis. International Journal of Health Geographics, 2011, 10, 63.	1.2	24